Home ➤ Life Science ➤ Biotechnology ➤ Immuno-Oncology Market
Immuno-Oncology Market
Published date: March 2025 • Formats:
Request Sample Schedule a Call

Global Immuno-Oncology Market By Treatment Type (Immune Checkpoint Inhibitors, CAR T-cell Therapy, mAbs, Cancer Vaccines, and Oncolytic Virus Therapy), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

  • Published date: March 2025
  • Report ID: 143626
  • Number of Pages: 250
  • Format:
  • keyboard_arrow_up

  • Table of Contents

    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Market Snapshot
      • 1.3. Market Overview
      • 1.4. Segment Overview
      • 1.5. Regional Overview
      • 1.6. Competitive Landscape
      • 1.7. Taxonomy
    • 2. Global Market Overview
      • 2.1. Global Market Insights and Industry Overview
      • 2.2. Market Dynamics
        • 2.2.1. Favourable Government Policies and Funding
        • 2.2.2. Severe Side Effects of Treatments
        • 2.2.3. Expansion of Combination Therapies
        • 2.2.4. Key Immuno-Oncology Market Trends
      • 2.3. Regulatory Framework
      • 2.4. Opportunity Map Analysis
      • 2.5. Opportunity Orbits
      • 2.6. PESTLE Analysis
      • 2.7. PORTER’S Five Force Analysis
      • 2.8. Drivers & Restraints Impact Analysis
      • 2.9. Value Chain Analysis
        • 2.9.1. List of Raw Materials Suppliers
        • 2.9.2. List of Immuno-Oncology Manufacturers
        • 2.9.3. List of Dealer/Distributors
      • 2.10. Regional Market Share and BPS Analysis
      • 2.11. Impact of Macro-economic Factors/Geopolitical Factors
    • 3. Global Immuno-Oncology Market Analysis and Forecast, By Segment, 2019-2033
      • 3.1. Key Findings
      • 3.2. Global Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Treatment Type, 2019-2033
      • 3.3. Global Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
        • 3.3.1. Immune Checkpoint Inhibitors
          • 3.3.1.1. Insights
          • 3.3.1.2. Key Takeaways
        • 3.3.2. CAR T-cell Therapy
          • 3.3.2.1. Insights
          • 3.3.2.2. Key Takeaways
        • 3.3.3. mAbs
          • 3.3.3.1. Insights
          • 3.3.3.2. Key Takeaways
        • 3.3.4. Cancer Vaccines
          • 3.3.4.1. Insights
          • 3.3.4.2. Key Takeaways
        • 3.3.5. Oncolytic Virus Therapy
          • 3.3.5.1. Insights
          • 3.3.5.2. Key Takeaways
    • 4. Global Immuno-Oncology Market Analysis and Forecast, By Region, 2019-2033
      • 4.1. Key Findings
      • 4.2. Global Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Region, 2019-2033
        • 4.2.1. North America
          • 4.2.1.1. Regional Insights
        • 4.2.2. Europe
          • 4.2.2.1. Regional Insights
        • 4.2.3. Asia Pacific
          • 4.2.3.1. Regional Insights
        • 4.2.4. Latin America
          • 4.2.4.1. Regional Insights
        • 4.2.5. Middle East & Africa
          • 4.2.5.1. Regional Insights
      • 4.3. Global Immuno-Oncology Market Attractiveness Analysis, By Region
    • 5. North America Immuno-Oncology Market Analysis and Forecast, 2019-2033
      • 5.1. Key Findings
      • 5.2. North America Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Treatment Type, 2019-2033
      • 5.3. North America Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
      • 5.4. North America Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Application, 2019-2033
      • 5.5. North America Immuno-Oncology Market Attractiveness Analysis, By Application
      • 5.6. North America Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
      • 5.7. North America Immuno-Oncology Market Attractiveness Analysis, By Country
        • 5.7.1. The US
        • 5.7.2. Canada
    • 6. Europe Immuno-Oncology Market Analysis and Forecast, 2019-2033
      • 6.1. Key Findings
      • 6.2. Europe Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Treatment Type, 2019-2033
      • 6.3. Europe Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
      • 6.4. Europe Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Application, 2019-2033
      • 6.5. Europe Immuno-Oncology Market Attractiveness Analysis, By Application
      • 6.6. Europe Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
      • 6.7. Europe Immuno-Oncology Market Attractiveness Analysis, By Country
        • 6.7.1. Germany
        • 6.7.2. The UK
        • 6.7.3. France
        • 6.7.4. Spain
        • 6.7.5. Italy
        • 6.7.6. Russia
        • 6.7.7. Netherland
        • 6.7.8. Rest of Europe
    • 7. Asia Pacific Immuno-Oncology Market Analysis and Forecast, 2019-2033
      • 7.1. Key Findings
      • 7.2. Asia Pacific Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Treatment Type, 2019-2033
      • 7.3. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
      • 7.4. Asia Pacific Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Application, 2019-2033
      • 7.5. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Application
      • 7.6. Asia Pacific Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
      • 7.7. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Country
        • 7.7.1. China
        • 7.7.2. Japan
        • 7.7.3. South Korea
        • 7.7.4. India
        • 7.7.5. Australia
        • 7.7.6. New Zealand
        • 7.7.7. Singapore
        • 7.7.8. Thailand
        • 7.7.9. Vietnam
        • 7.7.10. Rest of Asia Pacific
    • 8. Latin America Immuno-Oncology Market Analysis and Forecast, 2019-2033
      • 8.1. Key Findings
      • 8.2. Latin America Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Treatment Type, 2019-2033
      • 8.3. Latin America Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
      • 8.4. Latin America Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Application, 2019-2033
      • 8.5. Latin America Immuno-Oncology Market Attractiveness Analysis, By Application
      • 8.6. Latin America Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
      • 8.7. Latin America Immuno-Oncology Market Attractiveness Analysis, By Country
        • 8.7.1. Brazil
        • 8.7.2. Mexico
        • 8.7.3. Rest of Latin America
    • 9. Middle East & Africa Immuno-Oncology Market Analysis and Forecast, 2019-2033
      • 9.1. Key Findings
      • 9.2. Middle East & Africa Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Treatment Type, 2019-2033
      • 9.3. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
      • 9.4. Middle East & Africa Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Application, 2019-2033
      • 9.5. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Application
      • 9.6. Middle East & Africa Immuno-Oncology Market Size Value (US$ Bn) Analysis, Opportunity and Forecast, By Country, 2019-2033
      • 9.7. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Country
        • 9.7.1. South Africa
        • 9.7.2. Saudi Arabia
        • 9.7.3. UAE
        • 9.7.4. Rest of Middle East & Africa
    • 10. Competitive Landscape & Company Profiles
      • 10.1. Market Competition Scenario Analysis, By Company
      • 10.1.1. Key Takeaways
      • 10.2. Overview of Major Market Players
      • 10.3. Competitor Landscape
      • 10.4. Strategic Mapping
      • 10.5. Company Life Cycle Analysis
      • 10.6. Company Market Share Analysis
      • 10.7. Company Profiles
        • 10.7.1. Merck & Co.
          • 10.7.1.1. Company Details
          • 10.7.1.2. Business Overview
          • 10.7.1.3. Product Portfolio
          • 10.7.1.4. Financial Insights
          • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.1.6. SWOT Analysis
          • 10.7.1.7. Geographic Footprint
        • 10.7.2. AstraZeneca
          • 10.7.2.1. Company Details
          • 10.7.2.2. Business Overview
          • 10.7.2.3. Product Portfolio
          • 10.7.2.4. Financial Insights
          • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.2.6. SWOT Analysis
          • 10.7.2.7. Geographic Footprint
        • 10.7.3. F. Hoffmann-La Roche Ltd
          • 10.7.3.1. Company Details
          • 10.7.3.2. Business Overview
          • 10.7.3.3. Product Portfolio
          • 10.7.3.4. Financial Insights
          • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.3.6. SWOT Analysis
          • 10.7.3.7. Geographic Footprint
        • 10.7.4. Bristol-Myers Squibb Company
          • 10.7.4.1. Company Details
          • 10.7.4.2. Business Overview
          • 10.7.4.3. Product Portfolio
          • 10.7.4.4. Financial Insights
          • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.4.6. SWOT Analysis
          • 10.7.4.7. Geographic Footprint
        • 10.7.5. Eli Lilly and Company
          • 10.7.5.1. Company Details
          • 10.7.5.2. Business Overview
          • 10.7.5.3. Product Portfolio
          • 10.7.5.4. Financial Insights
          • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.5.6. SWOT Analysis
          • 10.7.5.7. Geographic Footprint
        • 10.7.6. GSK plc.
          • 10.7.6.1. Company Details
          • 10.7.6.2. Business Overview
          • 10.7.6.3. Product Portfolio
          • 10.7.6.4. Financial Insights
          • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.6.6. SWOT Analysis
          • 10.7.6.7. Geographic Footprint
        • 10.7.7. BeiGene LTD.
          • 10.7.7.1. Company Details
          • 10.7.7.2. Business Overview
          • 10.7.7.3. Product Portfolio
          • 10.7.7.4. Financial Insights
          • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.7.6. SWOT Analysis
          • 10.7.7.7. Geographic Footprint
        • 10.7.8. Summit Therapeutics Inc.
          • 10.7.8.1. Company Details
          • 10.7.8.2. Business Overview
          • 10.7.8.3. Product Portfolio
          • 10.7.8.4. Financial Insights
          • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.8.6. SWOT Analysis
          • 10.7.8.7. Geographic Footprint
        • 10.7.9. Sanofi
          • 10.7.9.1. Company Details
          • 10.7.9.2. Business Overview
          • 10.7.9.3. Product Portfolio
          • 10.7.9.4. Financial Insights
          • 10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.9.6. SWOT Analysis
          • 10.7.9.7. Geographic Footprint
        • 10.7.10. Novartis AG
          • 10.7.10.1. Company Details
          • 10.7.10.2. Business Overview
          • 10.7.10.3. Product Portfolio
          • 10.7.10.4. Financial Insights
          • 10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.10.6. SWOT Analysis
          • 10.7.10.7. Geographic Footprint
        • 10.7.11. AbbVie Inc.
          • 10.7.11.1. Company Details
          • 10.7.11.2. Business Overview
          • 10.7.11.3. Product Portfolio
          • 10.7.11.4. Financial Insights
          • 10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.11.6. SWOT Analysis
          • 10.7.11.7. Geographic Footprint
        • 10.7.12. Amgen Inc.
          • 10.7.12.1. Company Details
          • 10.7.12.2. Business Overview
          • 10.7.12.3. Product Portfolio
          • 10.7.12.4. Financial Insights
          • 10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.12.6. SWOT Analysis
          • 10.7.12.7. Geographic Footprint
        • 10.7.13. Johnson & Johnson Services, Inc.
          • 10.7.13.1. Company Details
          • 10.7.13.2. Business Overview
          • 10.7.13.3. Product Portfolio
          • 10.7.13.4. Financial Insights
          • 10.7.13.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.13.6. SWOT Analysis
          • 10.7.13.7. Geographic Footprint
    • 11. Methodology and Data Source
      • 11.1. Methodology/Research Approach
      • 11.2. Market Size Estimation
      • 11.3. Market Breakdown and Data Triangulation
      • 11.4. Data Source
      • 11.5. Secondary Sources
      • 11.6. Primary Sources
      • 11.7. Appendix
      • 11.8. Disclaimer

    List of Tables

    • Table 1. Global Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 2. Global Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 3. Global Immuno-Oncology Market Value (US$ Bn), By Region, 2019-2033
    • Table 4. North America Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 5. North America Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 6. North America Immuno-Oncology Market Value (US$ Bn), By Country, 2019-2033
    • Table 7. The US Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 8. The US Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 9. Canada Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 10. Canada Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 11. Europe Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 12. Europe Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 13. Europe Immuno-Oncology Market Value (US$ Bn), By Country, 2019-2033
    • Table 14. Germany Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 15. Germany Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 16. The UK Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 17. The UK Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 18. France Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 19. France Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 20. Spain Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 21. Spain Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 22. Italy Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 23. Italy Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 24. Russia Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 25. Russia Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 26. Netherland Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 27. Netherland Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 28. Rest of Europe Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 29. Rest of Europe Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 30. Asia Pacific Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 31. Asia Pacific Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 32. Asia Pacific Immuno-Oncology Market Value (US$ Bn), By Country, 2019-2033
    • Table 33. China Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 34. China Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 35. India Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 36. India Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 37. Japan Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 38. Japan Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 39. South Korea Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 40. South Korea Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 41. Australia Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 42. Australia Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 43. New Zealand Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 44. New Zealand Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 45. Singapore Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 46. Singapore Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 47. Thailand Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 48. Thailand Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 49. Vietnam Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 50. Vietnam Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 51. Rest of Asia Pacific Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 52. Rest of Asia Pacific Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 53. Latin America Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 54. Latin America Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 55. Latin America Immuno-Oncology Market Value (US$ Bn), By Country, 2019-2033
    • Table 56. Brazil Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 57. Brazil Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 58. Mexico Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 59. Mexico Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 60. Rest of Latin America Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 61. Rest of Latin America Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 62. Middle East & Africa Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 63. Middle East & Africa Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 64. Middle East & Africa Immuno-Oncology Market Value (US$ Bn), By Country, 2019-2033
    • Table 65. South Africa Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 66. South Africa Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 67. Saudi Arabia Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 68. Saudi Arabia Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 69. UAE Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 70. UAE Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033
    • Table 71. Rest of Middle East & Africa Immuno-Oncology Market Value (US$ Bn), By Treatment Type, 2019-2033
    • Table 72. Rest of Middle East & Africa Immuno-Oncology Market Value (US$ Bn), By Application, 2019-2033

    List of Figures

    • Figure 1. Global Immuno-Oncology Market Snapshot: Market Value (US$ Bn), 2019-2033
    • Figure 2. Opportunity Map
    • Figure 3. Opportunity Orbit
    • Figure 4. Regional Market Share and BPS Analysis in Immuno-Oncology Market
    • Figure 5. Global Immuno-Oncology Market Analysis, By Treatment Type, 2019, 2023 and 2033
    • Figure 6. Global Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
    • Figure 7. Global Immuno-Oncology Market Analysis, By Application, 2019, 2023 and 2033
    • Figure 8. Global Immuno-Oncology Market Attractiveness Analysis, By Application
    • Figure 9. Global Immuno-Oncology Market Analysis, By Region, 2019, 2023 and 2033
    • Figure 10. Global Immuno-Oncology Market Attractiveness Analysis, By Region
    • Figure 11. North America Immuno-Oncology Market Analysis, By Treatment Type, 2019, 2023 and 2033
    • Figure 12. North America Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
    • Figure 13. North America Immuno-Oncology Market (US$ Bn), by Immune Checkpoint Inhibitors, 2019-2033
    • Figure 14. North America Immuno-Oncology Market (US$ Bn), by CAR T-cell Therapy, 2019-2033
    • Figure 15. North America Immuno-Oncology Market (US$ Bn), by mAbs, 2019-2033
    • Figure 16. North America Immuno-Oncology Market (US$ Bn), by Cancer Vaccines, 2019-2033
    • Figure 17. North America Immuno-Oncology Market (US$ Bn), by Oncolytic Virus Therapy, 2019-2033
    • Figure 18. North America Immuno-Oncology Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 19. North America Immuno-Oncology Market Attractiveness Analysis, By Country
    • Figure 20. Europe Immuno-Oncology Market Analysis, By Treatment Type, 2019, 2023 and 2033
    • Figure 21. Europe Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
    • Figure 22. Europe Immuno-Oncology Market (US$ Bn), by Immune Checkpoint Inhibitors, 2019-2033
    • Figure 23. Europe Immuno-Oncology Market (US$ Bn), by CAR T-cell Therapy, 2019-2033
    • Figure 24. Europe Immuno-Oncology Market (US$ Bn), by mAbs, 2019-2033
    • Figure 25. Europe Immuno-Oncology Market (US$ Bn), by Cancer Vaccines, 2019-2033
    • Figure 26. Europe Immuno-Oncology Market (US$ Bn), by Oncolytic Virus Therapy, 2019-2033
    • Figure 27. Europe Immuno-Oncology Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 28. Europe Immuno-Oncology Market Attractiveness Analysis, By Country
    • Figure 29. Asia Pacific Immuno-Oncology Market Analysis, By Treatment Type, 2019, 2023 and 2033
    • Figure 30. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
    • Figure 31. Asia Pacific Immuno-Oncology Market (US$ Bn), by Immune Checkpoint Inhibitors, 2019-2033
    • Figure 32. Asia Pacific Immuno-Oncology Market (US$ Bn), by CAR T-cell Therapy, 2019-2033
    • Figure 33. Asia Pacific Immuno-Oncology Market (US$ Bn), by mAbs, 2019-2033
    • Figure 34. Asia Pacific Immuno-Oncology Market (US$ Bn), by Cancer Vaccines, 2019-2033
    • Figure 35. Asia Pacific Immuno-Oncology Market (US$ Bn), by Oncolytic Virus Therapy, 2019-2033
    • Figure 36. Asia Pacific Immuno-Oncology Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 37. Asia Pacific Immuno-Oncology Market Attractiveness Analysis, By Country
    • Figure 38. Latin America Immuno-Oncology Market Analysis, By Treatment Type, 2019, 2023 and 2033
    • Figure 39. Latin America Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
    • Figure 40. Latin America Immuno-Oncology Market (US$ Bn), by Immune Checkpoint Inhibitors, 2019-2033
    • Figure 41. Latin America Immuno-Oncology Market (US$ Bn), by CAR T-cell Therapy, 2019-2033
    • Figure 42. Latin America Immuno-Oncology Market (US$ Bn), by mAbs, 2019-2033
    • Figure 43. Latin America Immuno-Oncology Market (US$ Bn), by Cancer Vaccines, 2019-2033
    • Figure 44. Latin America Immuno-Oncology Market (US$ Bn), by Oncolytic Virus Therapy, 2019-2033
    • Figure 45. Latin America Immuno-Oncology Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 46. Latin America Immuno-Oncology Market Attractiveness Analysis, By Country
    • Figure 47. Middle East & Africa Immuno-Oncology Market Analysis, By Treatment Type, 2019, 2023 and 2033
    • Figure 48. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Treatment Type
    • Figure 49. Middle East & Africa Immuno-Oncology Market (US$ Bn), by Immune Checkpoint Inhibitors, 2019-2033
    • Figure 50. Middle East & Africa Immuno-Oncology Market (US$ Bn), by CAR T-cell Therapy, 2019-2033
    • Figure 51. Middle East & Africa Immuno-Oncology Market (US$ Bn), by mAbs, 2019-2033
    • Figure 52. Middle East & Africa Immuno-Oncology Market (US$ Bn), by Cancer Vaccines, 2019-2033
    • Figure 53. Middle East & Africa Immuno-Oncology Market (US$ Bn), by Oncolytic Virus Therapy, 2019-2033
    • Figure 54. Middle East & Africa Immuno-Oncology Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 55. Middle East & Africa Immuno-Oncology Market Attractiveness Analysis, By Country
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Immuno-Oncology Market
  • 143626
  • March 2025
    • ★★★★★
      ★★★★★
    • (142)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options